TMCnet News
Hyperphosphatemia In Chronic Kidney Disease Therapeutics Report 2016 - Pipeline Review of 9 Companies & Approx 15 Molecules - Research and MarketsResearch and Markets has announced the addition of the "Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016" report to their offering. Hyperphosphatemia In Chronic Kidney Disease pipeline therapeutics constitutes close to 15 molecules, out of which approximately 14 molecules are developed by Companies and remaining by Universities/Institutes. Our latest report 'Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Hyperphosphatemia In Chronic Kidney Disease Hyperphosphatemia, that is, abnormally high serum phosphate evels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 3, 1, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/mpvm9f/hyperphosphatemia
View source version on businesswire.com: http://www.businesswire.com/news/home/20160721005625/en/ |
